Skip to main content


Presenter: Alan Baer, Johns Hopkins University School of Medicine, Baltimore, USA.

Wednesday 12 June: 16:15–17:45 (Abstract OP0039)

The IM101-603 investigators randomly assigned participants to receive abatacept or placebo for 24 weeks, followed by open-label abatacept for approximately 6 months. The primary outcome measure is change in EULAR Sjögren's Syndrome Disease Activity Index from baseline to week 24.

More on this trial